Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBT (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of EBT data on record, last reported at -$48.2 million in Q3 2025.

  • For Q3 2025, EBT fell 51.0% year-over-year to -$48.2 million; the TTM value through Sep 2025 reached -$161.2 million, down 115.02%, while the annual FY2024 figure was -$55.6 million, 69.06% up from the prior year.
  • EBT reached -$48.2 million in Q3 2025 per GOSS's latest filing, down from -$38.3 million in the prior quarter.
  • Across five years, EBT topped out at $53.7 million in Q2 2024 and bottomed at -$59.0 million in Q3 2022.
  • Average EBT over 4 years is -$40.0 million, with a median of -$44.7 million recorded in 2024.
  • Peak YoY movement for EBT: surged 226.29% in 2024, then plummeted 171.32% in 2025.
  • A 4-year view of EBT shows it stood at -$57.2 million in 2022, then increased by 9.2% to -$52.0 million in 2023, then surged by 31.79% to -$35.4 million in 2024, then plummeted by 36.07% to -$48.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$48.2 million in Q3 2025, -$38.3 million in Q2 2025, and -$39.3 million in Q1 2025.